Product
Universal Donor Expanded TGF-beta-imprinted NK Cells
Aliases
Allogeneic TGFBi Expanded NK Cells, UD TGF-betai NK Cells, Universal Donor TGF-beta Imprinted Expanded NK Cells
2 clinical trials
3 indications
Indication
Breast Cancer, Stage IVIndication
Breast CarcinomaIndication
Multiple MyelomaClinical trial
Phase 1b/2 Study of Naxitamab (Danyelza), Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells in Advanced GD2-expressing Breast Cancers (DiG NKs)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase Ib Study of TGFbi NK Cells and Isatuximab for Myeloma Relapsed/Refractory to BCMA Targeting TherapyStatus: Recruiting, Estimated PCD: 2024-12-31